You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

HEMANGEOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Hemangeol, and what generic alternatives are available?

Hemangeol is a drug marketed by Pierre Fabre and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-seven patent family members in thirty-one countries.

The generic ingredient in HEMANGEOL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Hemangeol

A generic version of HEMANGEOL was approved as propranolol hydrochloride by INNOGENIX on October 22nd, 1985.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for HEMANGEOL?
  • What are the global sales for HEMANGEOL?
  • What is Average Wholesale Price for HEMANGEOL?
Drug patent expirations by year for HEMANGEOL
Drug Prices for HEMANGEOL

See drug prices for HEMANGEOL

Recent Clinical Trials for HEMANGEOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Christiana Care Health ServicesPhase 1
Columbia UniversityPhase 2
United States Department of DefenseEarly Phase 1

See all HEMANGEOL clinical trials

Pharmacology for HEMANGEOL
Paragraph IV (Patent) Challenges for HEMANGEOL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
HEMANGEOL Oral Solution propranolol hydrochloride 4.28 mg/mL 205410 1 2022-07-21

US Patents and Regulatory Information for HEMANGEOL

HEMANGEOL is protected by two US patents.

Patents protecting HEMANGEOL

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD TO TREAT HEMANGIOMA.

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD TO TREAT INFANTILE HEMANGIOMA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pierre Fabre HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pierre Fabre HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for HEMANGEOL

See the table below for patents covering HEMANGEOL around the world.

Country Patent Number Title Estimated Expiration
Colombia 6270209 UN BETA BLOQUEANTE PARA EL TRATAMIENTO DE LOS HEMANGIOMAS ⤷  Sign Up
Denmark 2233135 ⤷  Sign Up
European Patent Office 2050441 Utilisation de bêtabloquants pour la fabrication d'un médicament pour le traitement d'hémangiomes (Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.